ProQR Therapeutics (NASDAQ:PRQR) Short Interest Update

ProQR Therapeutics (NASDAQ:PRQR) was the recipient of a significant decline in short interest in November. As of November 15th, there was short interest totalling 413,800 shares, a decline of 38.9% from the October 31st total of 677,600 shares. Based on an average daily volume of 1,360,000 shares, the days-to-cover ratio is currently 0.3 days.

Hedge Funds Weigh In On ProQR Therapeutics

A number of hedge funds have recently made changes to their positions in the business. Acadian Asset Management LLC acquired a new position in ProQR Therapeutics during the 1st quarter worth $56,000. OneDigital Investment Advisors LLC grew its holdings in ProQR Therapeutics by 37.0% during the 3rd quarter. OneDigital Investment Advisors LLC now owns 57,550 shares of the biopharmaceutical company’s stock worth $105,000 after acquiring an additional 15,550 shares in the last quarter. BNP Paribas Financial Markets grew its holdings in ProQR Therapeutics by 14.2% during the 3rd quarter. BNP Paribas Financial Markets now owns 58,801 shares of the biopharmaceutical company’s stock worth $107,000 after acquiring an additional 7,300 shares in the last quarter. Finally, Privium Fund Management B.V. grew its holdings in ProQR Therapeutics by 4.4% during the 2nd quarter. Privium Fund Management B.V. now owns 5,580,725 shares of the biopharmaceutical company’s stock worth $9,208,000 after acquiring an additional 236,279 shares in the last quarter. Hedge funds and other institutional investors own 32.65% of the company’s stock.

ProQR Therapeutics Stock Up 6.7 %

Shares of PRQR traded up $0.23 on Thursday, hitting $3.67. 416,651 shares of the stock traded hands, compared to its average volume of 522,656. The firm has a market capitalization of $299.77 million, a P/E ratio of -11.47 and a beta of 0.26. The stock’s 50 day moving average is $3.00 and its two-hundred day moving average is $2.26. ProQR Therapeutics has a 1 year low of $1.33 and a 1 year high of $4.62.

Analyst Ratings Changes

Several equities analysts have recently commented on PRQR shares. HC Wainwright upped their price target on ProQR Therapeutics from $5.00 to $10.00 and gave the company a “buy” rating in a research note on Friday, November 8th. Raymond James raised ProQR Therapeutics from an “outperform” rating to a “strong-buy” rating and increased their target price for the stock from $6.00 to $14.00 in a research note on Tuesday, October 29th. One analyst has rated the stock with a hold rating, three have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, ProQR Therapeutics presently has a consensus rating of “Buy” and an average price target of $7.13.

About ProQR Therapeutics

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).